Matches in Wikidata for { <http://www.wikidata.org/entity/Q92262738> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- Q92262738 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92262738 description "scientific article published on 18 June 2019" @default.
- Q92262738 description "wetenschappelijk artikel" @default.
- Q92262738 description "наукова стаття, опублікована 18 червня 2019" @default.
- Q92262738 name "Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial" @default.
- Q92262738 name "Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial" @default.
- Q92262738 type Item @default.
- Q92262738 label "Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial" @default.
- Q92262738 label "Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial" @default.
- Q92262738 prefLabel "Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial" @default.
- Q92262738 prefLabel "Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial" @default.
- Q92262738 P1433 Q92262738-D1708931-3EC8-4635-8CE6-6711F95077DB @default.
- Q92262738 P1476 Q92262738-1BEE722F-43F3-4710-B4AA-5A6A1C70F6A4 @default.
- Q92262738 P2093 Q92262738-01544860-BF78-4423-AB76-B816B093F26E @default.
- Q92262738 P2093 Q92262738-070A847D-D48C-428E-B90B-2C95FA7A3118 @default.
- Q92262738 P2093 Q92262738-3157A27E-0A0C-4B4F-B040-7E3B71331BA9 @default.
- Q92262738 P2093 Q92262738-83C6DDC8-1D30-44E9-807A-6FEDD1BB80ED @default.
- Q92262738 P2093 Q92262738-951E77E3-22BE-4804-9EA2-5F83E1CF3B40 @default.
- Q92262738 P2860 Q92262738-1029E5A2-D9F6-4E1D-8207-913BDE0118CD @default.
- Q92262738 P2860 Q92262738-2B3DC822-CB97-496B-AADE-A675080782B8 @default.
- Q92262738 P2860 Q92262738-32DDE487-EF59-43AF-9277-B3482107BC81 @default.
- Q92262738 P2860 Q92262738-3AF6FA38-204B-4BF1-8905-26A63557EFC2 @default.
- Q92262738 P2860 Q92262738-74669972-22D6-4599-8B1D-855DB947E735 @default.
- Q92262738 P2860 Q92262738-A468DD91-737B-4B6E-9F5F-F14EE6F0CC00 @default.
- Q92262738 P2860 Q92262738-BA588A48-FF8C-4A53-AF42-C88E9F946942 @default.
- Q92262738 P2860 Q92262738-C26976F0-4006-465C-B8AA-4C0A98390ACE @default.
- Q92262738 P2860 Q92262738-C53ADC78-3084-4CAC-AEF8-F475FBA70A2F @default.
- Q92262738 P2860 Q92262738-CA967A12-30AD-4B51-BAB4-ABE9E9F48DF7 @default.
- Q92262738 P2860 Q92262738-F82B7D2D-BB2F-4821-B517-F6DDA4647DC7 @default.
- Q92262738 P304 Q92262738-EFF7F689-4AA4-43B9-BD78-CD653397AE21 @default.
- Q92262738 P31 Q92262738-53107631-D521-4F3C-86DC-7F4B188D6287 @default.
- Q92262738 P356 Q92262738-BB45E476-2031-4253-8444-FA10165C2D2E @default.
- Q92262738 P433 Q92262738-E063E835-8C44-4076-BA72-31126D420EF7 @default.
- Q92262738 P478 Q92262738-3A59F86C-E7C6-4531-B736-6E6697529C48 @default.
- Q92262738 P50 Q92262738-4EA9FDB2-B0E4-4B13-A4C5-F0EDE565E612 @default.
- Q92262738 P50 Q92262738-66F780AD-A787-44B5-8DE4-E5C28A673260 @default.
- Q92262738 P50 Q92262738-8EC3CF9F-E3CF-494D-A249-5130C2EEE60D @default.
- Q92262738 P50 Q92262738-E81A562D-065F-48CB-B821-6798CF7BD784 @default.
- Q92262738 P577 Q92262738-6D4C2244-3BB0-49AD-BC14-10DDF758C3C2 @default.
- Q92262738 P698 Q92262738-B8014B73-5E5D-40AC-904D-84FEECACC41B @default.
- Q92262738 P921 Q92262738-2189A564-41C7-494E-8712-1B70CFDFB895 @default.
- Q92262738 P932 Q92262738-E6FED03D-2A4C-4505-9271-6CE4DF68C09B @default.
- Q92262738 P356 DOM.13791 @default.
- Q92262738 P698 31124299 @default.
- Q92262738 P1433 Q5270109 @default.
- Q92262738 P1476 "Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial" @default.
- Q92262738 P2093 "Cecile Dessapt-Baradez" @default.
- Q92262738 P2093 "Dalong Zhu" @default.
- Q92262738 P2093 "Fernando J Lavalle-González" @default.
- Q92262738 P2093 "Gagik R Galstyan" @default.
- Q92262738 P2093 "Mike Baxter" @default.
- Q92262738 P2860 Q36370038 @default.
- Q92262738 P2860 Q37067081 @default.
- Q92262738 P2860 Q37278100 @default.
- Q92262738 P2860 Q38611795 @default.
- Q92262738 P2860 Q51280414 @default.
- Q92262738 P2860 Q52595142 @default.
- Q92262738 P2860 Q57026285 @default.
- Q92262738 P2860 Q58456995 @default.
- Q92262738 P2860 Q59372334 @default.
- Q92262738 P2860 Q60707174 @default.
- Q92262738 P2860 Q91091403 @default.
- Q92262738 P304 "1967-1972" @default.
- Q92262738 P31 Q13442814 @default.
- Q92262738 P356 "10.1111/DOM.13791" @default.
- Q92262738 P433 "8" @default.
- Q92262738 P478 "21" @default.
- Q92262738 P50 Q37373997 @default.
- Q92262738 P50 Q42317155 @default.
- Q92262738 P50 Q87701809 @default.
- Q92262738 P50 Q90014123 @default.
- Q92262738 P577 "2019-06-18T00:00:00Z" @default.
- Q92262738 P698 "31124299" @default.
- Q92262738 P921 Q3025883 @default.
- Q92262738 P932 "6772132" @default.